Clinical Trials for Other Solid Tumor

A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates luveltamab tazevibulin, an anti-FOLR1 antibody-drug conjugate, in adult patients with previously treated advanced or metastatic non-squamous/adenocarcinoma or adenosquamous NSCLC, targeting FOLR1-expressing tumors. The study includes patients with disease progression who have undergone two to four prior systemic therapies.

ClinicalTrials.gov ID: NCT06555263

Phase 1-2 Trial of Systemically Administered VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selected Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates VSV-IFNβ-NIS, an investigational oncolytic virus therapy that enhances immune response, in combination with the checkpoint inhibitor pembrolizumab, for patients with refractory non-small cell lung cancer (NSCLC) and neuroendocrine carcinoma (NEC) who have progressed despite prior PD-1/PD-L1 inhibitor therapy.

ClinicalTrials.gov ID: NCT03647163

A Randomized Pivotal Study Assessing the Efficacy of Targeted Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-small Cell Lung Cancer (NSCLC) Origin

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates adults with NSCLC who have untreated brain metastases, focusing on the efficacy of combining Exablate focused ultrasound with pembrolizumab, an immunotherapy targeting PD-1, versus pembrolizumab alone. Participants must have negative EGFR and ALK statuses and appropriate performance scores.

ClinicalTrials.gov ID: NCT05317858

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial compares the efficacy and safety of acasunlimab, a bispecific antibody targeting PDL1 and 4-1BB, combined with pembrolizumab, against docetaxel in patients with PD-L1 positive metastatic non-small cell lung cancer who have previously received PD-1/PD-L1 inhibitors and platinum-based chemotherapy. Eligible participants must have measurable stage IV disease with good performance status and have been treated with one or two prior lines of therapy.

ClinicalTrials.gov ID: NCT06635824

A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer: TOP2201

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the combination of alirocumab, a PCSK9 inhibitor, with cemiplimab, a PD-1 inhibitor, in patients with metastatic non-small cell lung cancer who have progressed after prior PD-1 therapies. It is aimed at those with specific molecular alterations such as EGFR, ALK, and ROS1, following progression on targeted treatments.

ClinicalTrials.gov ID: NCT05553834

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression of 1% to 49%

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial compares the first-line treatment of stage IV or recurrent non-squamous non-small cell lung cancer in patients with PD-L1 expression of 1% to 49%, using Nivolumab and Relatlimab (a LAG-3 inhibitor) with chemotherapy versus Pembrolizumab with chemotherapy.

ClinicalTrials.gov ID: NCT06561386

LUNG-IST-127: A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab (CP) for Patients With Metastatic sqNSCLC With Disease Control Following Induction Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients with metastatic squamous non-small cell lung cancer who have achieved disease control after induction therapy, and evaluates the maintenance treatment effect of cabozantinib, a multi-receptor tyrosine kinase inhibitor, plus pembrolizumab, a PD-1 checkpoint inhibitor.

ClinicalTrials.gov ID: NCT05613413

A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial is for adult patients with advanced MTAP-null solid tumors, evaluating the safety and efficacy of the investigational drug AMG 193, an oral MTA-cooperative PRMT5 inhibitor, alone and in combination with the chemotherapy agent docetaxel. Participants must have a performance status of 0 to 1 and meet specific health criteria.

ClinicalTrials.gov ID: NCT05094336

A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets adult patients with advanced non-squamous NSCLC, Stage IV or recurrent, who have failed first-line checkpoint inhibitor therapy, and involves treatment with intravenous atezolizumab, a PD-L1 inhibitor, alongside tocilizumab, an IL-6 receptor antibody, administered every 21 days.

ClinicalTrials.gov ID: NCT04691817

A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial evaluates the addition of oral restorative microbiota therapy (RMT) to standard chemotherapy (cisplatin/pemetrexed or carboplatin/pemetrexed) and durvalumab, a PD-L1 targeting monoclonal antibody, in untreated patients with advanced or metastatic adenocarcinoma NSCLC, excluding those with EGFR or ALK mutations.

ClinicalTrials.gov ID: NCT04105270